CHÂTILLON, France, June 29, 2026
DBV Technologies announced an update on the Biologics License Application (BLA) for its investigational VIASKIN® Peanut Patch, confirming that the company now expects to submit the application during the third quarter of 2026 for the treatment of peanut allergy in children aged 4 through 7 years. The revised timeline follows extensive and collaborative discussions with the U.S. Food and Drug Administration (FDA) aimed at ensuring a complete, efficient, and timely regulatory review once the application is filed. Importantly, the FDA has not requested any additional clinical or non-clinical data.
Instead, the Agency provided actionable recommendations regarding the organization, mapping, and formatting of existing Chemistry, Manufacturing and Controls (CMC) and biostatistical data within the BLA. DBV stated it will use the additional time to incorporate this feedback, strengthening the overall submission package while maintaining its confidence in the existing data supporting the VIASKIN Peanut Patch.
FDA Feedback Focuses on Submission Quality
According to DBV Technologies, the ongoing engagement with the FDA has included multiple meetings, information exchanges, and regulatory filings under the Investigational New Drug (IND) application for VIASKIN Peanut Patch. The company emphasized that these discussions were designed to optimize the BLA before formal submission rather than resolve deficiencies in the clinical program. Chief Executive Officer Daniel Tassé noted that the VIASKIN Peanut Patch represents a novel and complex product with no direct regulatory precedent, making early collaboration with the FDA particularly valuable.
He explained that many of the detailed regulatory discussions occurring before submission would typically take place after a BLA has already been filed, allowing DBV to proactively address regulatory expectations and potentially facilitate a smoother review process. The company believes incorporating the FDA’s recommendations now will help improve the efficiency of the future review without requiring additional studies or delaying long-term development plans.
Advertisement
VIASKIN Peanut Patch Targets Pediatric Food Allergy
The VIASKIN Peanut Patch is being developed as a non-invasive epicutaneous immunotherapy (EPIT) designed to treat peanut allergy, one of the most common and potentially life-threatening food allergies affecting children worldwide. Unlike oral immunotherapy approaches, the VIASKIN Patch delivers microgram quantities of peanut allergen through intact skin, leveraging the skin’s immune-tolerizing properties to gradually desensitize the immune system without requiring ingestion of the allergen. DBV believes this unique technology could offer an important treatment option for young children by reducing the risk of severe allergic reactions while providing a convenient and well-tolerated therapy.
The current BLA specifically targets children between four and seven years of age, while the company continues separate clinical development programs evaluating the patch in toddlers aged one through three years. If approved, VIASKIN Peanut Patch could become a significant advancement in pediatric food allergy management through its innovative transdermal immunotherapy platform.
Regulatory Milestone Supports Long-Term Growth Strategy
The anticipated Q3 2026 BLA submission marks an important regulatory milestone for DBV Technologies, which remains focused on developing innovative therapies for food allergies and immunologic diseases with significant unmet medical need. Headquartered in Châtillon, France, with North American operations in Warren, New Jersey, the late-stage biopharmaceutical company continues advancing its proprietary VIASKIN platform across multiple clinical programs.
The company’s latest regulatory update reinforces that development remains on track despite the modest filing timeline adjustment, as the delay reflects efforts to optimize the submission rather than address deficiencies in efficacy, safety, or manufacturing. Investors and clinicians will closely monitor the upcoming BLA submission later this year, as FDA acceptance would represent the next major step toward potential approval of the VIASKIN Peanut Patch as a first-in-class epicutaneous immunotherapy for young children living with peanut allergy.
Source: DBV Technologies, press release
